- Open Access
microRNA-150: a promising novel biomarker for hepatitis B virus-related hepatocellular carcinoma
© Yu et al. 2015
Received: 20 March 2015
Accepted: 15 July 2015
Published: 28 July 2015
Chronic hepatitis B virus (HBV) infection is a known major etiological factor for hepatocellular carcinoma (HCC) development. Alpha-fetoprotein (AFP) is widely used to detect primary HCC, whereas its sensitivity and specificity are not satisfying. Recently, circulating microRNAs (miRNAs) have been reported to be promising biomarkers for diagnosing and monitoring cancers. This study was conducted to detect the application of serum miR-150 in the diagnosis and prognosis of HBV-related HCC.
The expression of miR-150 was evaluated using a real-time quantitative RT-PCR in 350 serum samples (120 samples from controls, 110 from chronic hepatitis B (CHB) patients and 120 samples from HCC patients.
Serum miR-150 levels were significantly reduced in HCC patients, compared with healthy controls (P < 0.0001) and CHB patients (P < 0.0001). Serum miR-150 levels were increased after surgical operation (P < 0.0001) and decreased after tumor recurrence (P < 0.0001). Receiver operating characteristic curve (ROC) analyses suggested that serum miR-150 had significant diagnostic value for HBV-related HCC. It yielded an area under the curve (AUC) of ROC of 0.931 with 82.5 % sensitivity and 83.7 % specificity in discriminating HCC from healthy controls, and an AUC of ROC of 0.881 with 79.1 % sensitivity and 76.5 % specificity in discriminating HCC from CHB patients. Moreover, Kaplan-Meier curve analysis revealed that HCC patients with lower serum miR-150 had a significantly shortened overall survival (P < 0.0001). Univariate and Multivariable Cox regression analysis indicated that serum miR-150 level was an independent risk factor for overall survival (P < 0.0001 and P = 0.015, respectively).
Serum miR-150 can serve as a non-invasive biomarker for the diagnosis and prognosis of HCC patients.
Hepatocellular carcinoma (HCC) is one of the most common prevalent cancers, rated third in mortality worldwide . Although there are different viral and non-viral causes of HCC, almost 80 % of HCC patients are associated with hepatitis B virus (HBV) infection . Currently, most HCC patients have a poor prognosis with a relative low survive rate, which is due to their diagnosis at advanced stages with limited therapeutic options. Alpha-fetoprotein (AFP) is widely used to detect primary HCC but its sensitivity and specificity are disputed . Thus, it is prudent to search for more effective and reliable markers for diagnosis and prognosis of primary HCC.
MicroRNAs (miRNAs), a class of small non-coding RNAs, can regulate gene expression by binding to complementary sequences in the 3′-untranslated region of mRNAs [4–6]. Recently, miRNAs have been shown to be involved in several physiological processes such as development, apoptosis, proliferation, and differentiation, and even play a critical role in carcinogenesis [7–9]. In many cancers, aberrant expressions of tissue-miRNAs may lead to poor prognosis, suggesting that they can function as oncogenes or tumor suppressor genes [10, 11]. Apart from their tissue-specific origin and expression, miRNAs are also shown to be stable and detectable in many body fluids including serum and plasma . Increasing evidence has shown that circulating miRNAs have potential as non-invasive biomarker for HCC. For example, Xie et al. found that serum miR-101 levels were significantly down-regulated in the HBV-HCC patients and could differentiate HBV-HCC form HBV-associated liver cirrhosis . Notably, altered serum/plasma miRNAs levels are also associated with the development of HCC .
Our group previously reported that over-expression of miR-150 contributed to the suppression of activated hepatic stallate cells (HSCs) in liver fibrosis, resulting in the reduction of cell proliferation . Interestingly, Chang et al. found that Myc levels could be affected by miR-150 in Myc-mediated tumorigenesis . Zhang et al. further demonstrated that miR-150 could inhibit CD133-positive liver cancer stem cells by targeting c-Myb . Combined these, miR-150 might function as a tumour suppressor in HCC. In addition, a recent study showed that miR-150 is a factor of survival in non-small cell lung cancer and associated with poor prognosis . miR-150 also predicts a favorable prognosis in patients with epithelial ovarian cancer, and inhibits cell invasion and metastasis by suppressing transcriptional repressor ZEB1 . In this study, we evaluated whether serum miR-150 could serve as a new biomarker for the diagnosis and prognosis of HBV-related HCC patients.
HCC (n = 120)
CHB (n = 110)
Control (n = 120)
Mean ± SD
58 ± 10.4
55 ± 11.2
50 ± 9.5
Mean ± SD
293.7 ± 705.5
18.8 ± 16.5
3.1 ± 1.2
Tumor diameter (cm)
Moderate + Well
I + II
Samples processing and RNA extraction
The blood samples from all subjects were centrifuged at 3400 g for 7 min at room temperature, and the supernatants were transferred into Eppendorf tubes followed by further centrifugation at 12000 g for 10 min at 4 °C. Then the supernatants were stored at -80 °C pending RNA extraction. All blood samples were processed within 4 h after they were obtained. Total RNA containing small RNA was extracted from 500 μl of serum using a miRNeasy Mini Kit (Qiagen, Carlsbad, California, USA) according to the manufacturer’s instruction for liquid samples. DNase treatment (Qiagen, Carlsbad, California, USA) was carried out to remove any containing DNA. The final elution volume was 20 μl. All serum RNA preparations were quantified by NanoDrop 1000 (Nanodrop, Wilmingtion, Delaware, USA).
microRNA quantification by real-time quantitative RT-PCR
Serum miR-150 level was quantified in triplicate by qRT-PCR using TaqMan MicroRNA Assay Kits (Applied Biosystems, Foster City, CA). The reverse transcription reaction was performed in a 20 μl reaction volume using specific primer for miR-150 contained in the TaqMan MicroRNA Reverse Transcription kit (Applied Biosystems, Foster City, CA). For synthesis of cDNA, the reaction mixtures were sequentially incubated at 16 °C for 30 min, 42 °C for 30 min, and 85 °C for 5 min. According to the standard TaqMan MicroRNA assay protocol, real-time PCR was performed in ABI 7500 Real-Time PCR system (Applied Biosystems, Foster City, CA) with the following cycle: 95 °C for 10 min, followed by 40 cycles of 95 °C for 15 s and 60 °C for 60 s. Each PCR mixture (20 μl) included the reverse transcription products, TaqMan 2X Universal PCR Master Mix without UNG Amperase, miRNA-specific TaqMan probes, and primers supplied by Applied Biosystems. The cyclethreshold (Ct) values were calculated with the SDS 2.0.1 software (Applied Biosystems, Foster City, CA). The formula 2−⊿Ct was used to calculate the miRNA levels in serum, where ⊿Ct = mean (Ct of internal references) − Ct of target miRNA. The relative expression levels of miR-150 were calculated and normalized to miR-16 (Applied Biosystems, Foster City, CA) using the comparative⊿Ct method and the equation 2 −⊿Ct, as described previously .
ANOVA and χ 2 test were used to compare demographic characterization of study population. The significance of serum miR-150 levels was determined by Mann–Whitney U test. All tests were two-sided test and P < 0.05 was considered as statistically significant. Receiver operating characteristic (ROC) curves were generated to classify patients in different groups, as well as for the evaluation of the diagnostic potential of serum miR-150 via calculation of the area under the ROC curve (AUC), sensitivity and specificity according to standard formulas. Survival curves were plotted using the Kaplan–Meier method and analyzed using the log-rank test. Univariate and multivariate analyses of HCC prognostic factors were performed using the Cox proportional hazards model. Statistical analyses were performed with SPSS 13.0 (IBM, Armonk, NY).
Demographic and clinical characterizations of study population are summarized in Table 1. A total of 350 participants including 120 HCC patients, 110 CHB patients and 120 healthy controls were recruited into this study. There were no significant differences of age between patients with HCC patients, CHB patients and healthy controls (P = 0.562, ANOVA). The sex distribution in the HCC group was 75:45, in CHB group was 67:43 and in control group was 65:55 (P = 0.381, χ 2 test).
Expression profile of serum miR-150
The diagnostic value of serum miR-150 for HCC
Serum miR-150 level, clinical characteristics, liver function and survival in HCC patients
Correlation of serum miR-150 with clinicopathological data in pre-operative group
Number of cases
Tumor diameter (cm)
Moderate + Well
I + II
Univariate and multivariate analysis for the prognostic significance of clinicopathological characteristics and serum miR-150 levels in HCC
HR (95 % CI)b
HR (95 % CI)b
HCC is the leading cause of cancer mortality in many countries due to its high mortality rate . Screening for HCC allows early-stage diagnosis of the malignancy and potentially reduces mortality of the disease. Current diagnosis of HCC is based on imaging technology, serum AFP levels, and histology . These diagnostic tools have variable effectiveness for early diagnosis of HCC; cross-sectional imaging typically detects only tumors greater than 1 cm in diameter, and serologic studies also lack sensitivity and specificity in patients with small tumors . Based on these, investigators are attempting to search for more effective serum biomarker in HCC patients.
In the last decades, numerous studies have shown that aberrant miRNAs expression is associated with the development and progression of various types of human cancer, which indicates that miRNAs can be reliable biomarkers for cancers [27–29]. Tissue-specific miRNAs cannot be used on a wide scale because the procedure is invasive; however, use of serum miRNAs is noninvasive and thus more practical. Notably, serum miRNAs are remarkably stable and expression patterns seem to be tissue-specific, which makes it a good candidate for noninvasive cancer testing . The serum miRNAs were firstly detected in the patients with diffuse large B cell lymphoma, and subsequent studies have continually reported the presence of miRNAs in circulation system and body fluid, and revealed that miRNAs are potential diagnostic biomarkers and prognostic factors in cancers [12, 24, 30–32]. More recently, it was reported that plasma miR-155, miR-197, and miR-182 could be potential noninvasive biomarkers for early detection of lung cancer . Li et al. identified miR-18a as a potential marker for hepatitis B virus-related HCC Screening . Huang et al. found that plasma miR-29a and miR-92a have significant diagnostic value in advanced neoplasia . These reports prompted us to reveal more useful circulating miRNA markers for different types of cancer with a clinically satisfactory degree of sensitivity and specificity.
In the present study, it was found that serum miR-150 levels were significantly reduced in patients with HBV-related HCC when compared to those in healthy controls, which was consistent with the previous studies that indicated the reduction of miR-150 levels in HCC tissue and cell lines [34, 35]. It yielded an AUC of 0.931, with the sensitivity of 82.5 % and the specificity of 83.7 %. Chronic HBV infection is a known major etiological factor for HCC development . Therefore, we further determine whether serum miR-150 could discriminate HCC patients from CHB patients. Our results showed that serum miR-150 could discriminate HCC patients from CHB patients. It yielded an AUC of 0.881, with the sensitivity of 79.1 % and the specificity of 76.5 %. In addition, serum miR-150 levels were measured in 120 paired pre-operative and post-operative samples. We found that serum miR-150 levels were increased in patients with HCC after surgical resection of tumors. However, serum miR-150 levels were reduced again after tumor recurrence in paired post-operative and relapsed samples. These results suggested that miR-150 acts as a tumor suppressor in the development of HCC. The prediction of metastasis, recurrence, and prognosis in patients with HCC after hepatic resection is an important clinical issue that could determine the surgical therapeutic regimen. In this study, we observed that reduced miR-150 expression in HCC patients was correlated negatively with advanced TNM stages, which is highly correlated with the prognosis of HCC [37, 38]. These data showed that miR-150 could be used for the prediction of the prognosis of HCC. Consistent with this result, further study indicated that the down-regulated miR-150 was associated with poor survival for patients with HCC. The patients with low expression of serum miR-150 had lower survival rates. To our knowledge, it is the first report to evaluate the prognosis value of serum miR-150 in HCC. Moreover, the univariate and multivariate analysis with Cox regression models revealed that serum miR-150 could potentially serve as an independent risk predictor for the prognosis of HCC. Further study showed that miR-150 levels were reduced in CHB patients with Child-Pugh B compared with patients with Child-Pugh A. The similar results are also shown in HCC patients, suggesting that miR-150 level is associated with liver function.
The prediction of the prognosis and accurate patient stratification are crucial to optimise personalised treatment . Besides TNM stages, BCLC staging system is also an often used clinical classification for HCC patients [22, 40]. Our results showed that lower miR-150 level was found in patients with BCLC B stage compared with patients with BCLC A stage, suggesting that miR-150 is also associated with BCLC stage. Recently, it has been demonstrated that the multikinase inhibitor sorafenib has been validated to treat patients with advanced HCC . However, there is no advanced BCLC stage such as BCLC C stage, due to the reason that none with metastasis were included in this study. Our results showed that miR-150 might be a tumor suppressor. Therefore, it is speculated that miR-150 might be associated with tumor metastasis. Whether miR-150 could be tested as a biomarker for sorafenib efficacy should be studied in future. In addition, there are other limitations in this study. First, the sample size is relatively small and large samples are needed to the further validations of this marker. Second, where serum miRNAs come from or how organs release miRNAs into the blood is still unknown. Further studies are needed to prove it.
In conclusion, our findings suggested that serum miR-150 might serve as a novel diagnostic and prognostic marker for HCC. Our data serve as basis for further investigation, preferably in large prospective studies before miR-150 can be used as a noninvasive screening tool for HCC in routine clinical practice.
The project was supported by National Natural Science Foundation of China (81000176/H0317, 81100292/H0317), Zhejiang Provincial Natural Science Foundation of China (Y2090326, Y2110634) and Wang Bao-En Liver Fibrosis Foundation (20100002, 20120127) and the key disciplines in Colleges and Universities of Zhejiang Province.
- El-Serag HB, Marrero JA, Rudolph L, Reddy KR. Diagnosis and treatment of hepatocellular carcinoma. Gastroenterology. 2008;134:1752–63.PubMedView ArticleGoogle Scholar
- Xie Y, Yao Q, Butt AM, Guo J, Tian Z, Bao X, et al. Expression profiling of serum microRNA-101 in HBV-associated chronic hepatitis, liver cirrhosis, and hepatocellular carcinoma. Cancer Biol Ther. 2014;15:1248–55.PubMedView ArticleGoogle Scholar
- Zinkin NT, Grall F, Bhaskar K, Otu HH, Spentzos D, Kalmowitz B, et al. Serum proteomics and biomarkers in hepatocellular carcinoma and chronic liver disease. Clin Cancer Res. 2008;14:470–7.PubMedView ArticleGoogle Scholar
- Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004;116:281–97.PubMedView ArticleGoogle Scholar
- Fabbri M, Croce CM, Calin GA. MicroRNAs. Cancer J. 2008;14:1–6.PubMedView ArticleGoogle Scholar
- He L, Hannon GJ. MicroRNAs: small RNAs with a big role in gene regulation. Nat Rev Genet. 2004;5:522–31.PubMedView ArticleGoogle Scholar
- Miska EA. How microRNAs control cell division, differentiation and death. Curr Opin Genet Dev. 2005;15:563–8.PubMedView ArticleGoogle Scholar
- Kutay H, Bai S, Datta J, Motiwala T, Pogribny I, Frankel W, et al. Downregulation of miR-122 in the rodent and human hepatocellular carcinomas. J Cell Biochem. 2006;99:671–8.PubMed CentralPubMedView ArticleGoogle Scholar
- Su H, Yang JR, Xu T, Huang J, Xu L, Yuan Y, et al. MicroRNA-101, down-regulated in hepatocellular carcinoma, promotes apoptosis and suppresses tumorigenicity. Cancer Res. 2009;69:1135–42.PubMedView ArticleGoogle Scholar
- Volinia S, Calin GA, Liu CG, Ambs S, Cimmino A, Petrocca F, et al. A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci U S A. 2006;103:2257–61.PubMed CentralPubMedView ArticleGoogle Scholar
- Esquela-Kerscher A, Slack FJ. Oncomirs - microRNAs with a role in cancer. Nat Rev Cancer. 2006;6:259–69.PubMedView ArticleGoogle Scholar
- Mitchell PS, Parkin RK, Kroh EM, Fritz BR, Wyman SK, Pogosova-Agadjanyan EL, et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci U S A. 2008;105:10513–8.PubMed CentralPubMedView ArticleGoogle Scholar
- Qi P, Cheng SQ, Wang H, Li N, Chen YF, Gao CF. Serum microRNAs as biomarkers for hepatocellular carcinoma in Chinese patients with chronic hepatitis B virus infection. PLoS One. 2011;6:e28486.PubMed CentralPubMedView ArticleGoogle Scholar
- Zheng J, Lin Z, Dong P, Lu Z, Gao S, Chen X, et al. Activation of hepatic stellate cells is suppressed by microRNA-150. Int J Mol Med. 2013;32:17–24.PubMedGoogle Scholar
- Chang TC, Yu D, Lee YS, Wentzel EA, Arking DE, West KM, et al. Widespread microRNA repression by Myc contributes to tumorigenesis. Nat Genet. 2008;40:43–50.PubMed CentralPubMedView ArticleGoogle Scholar
- Zhang J, Luo N, Luo Y, Peng Z, Zhang T, Li S. microRNA-150 inhibits human CD133-positive liver cancer stem cells through negative regulation of the transcription factor c-Myb. Int J Oncol. 2012;40:747–56.PubMedGoogle Scholar
- Yin Q, Sun X, Yang G, Li X, Wu M, Zhao J. Increased expression of microRNA-150 is associated with poor prognosis in non-small cell lung cancer. Int J Clin Exp Pathol. 2015;8:842–6.PubMed CentralPubMedGoogle Scholar
- Jin M, Yang Z, Ye W, Xu H, Hua X. MicroRNA-150 predicts a favorable prognosis in patients with epithelial ovarian cancer, and inhibits cell invasion and metastasis by suppressing transcriptional repressor ZEB1. PLoS One. 2014;9:e103965.PubMed CentralPubMedView ArticleGoogle Scholar
- Hepatobiliary Surgery Group, Chinese Society of Surgery, Chinese Medical Association. 2004 guidelines for surgical treatment of primary hepatocellular carcinoma. Zhonghua Gan Zang Bing Za Zhi. 2005;13:329–30.Google Scholar
- Qin S. Guidelines on the diagnosis and treatment of primary liver cancer (2011 edition). Chin Clin Oncol. 2012;1:10.PubMedGoogle Scholar
- Pugh RN, Murray-Lyon IM, Dawson JL, Pietroni MC, Williams R. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg. 1973;60:646–9.PubMedView ArticleGoogle Scholar
- Llovet JM, Bru C, Bruix J. Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis. 1999;19:329–38.PubMedView ArticleGoogle Scholar
- Yao J, Liang L, Huang S, Ding J, Tan N, Zhao Y, et al. MicroRNA-30d promotes tumor invasion and metastasis by targeting Galphai2 in hepatocellular carcinoma. Hepatology. 2010;51:846–56.PubMedGoogle Scholar
- Li L, Guo Z, Wang J, Mao Y, Gao Q. Serum miR-18a: a potential marker for hepatitis B virus-related hepatocellular carcinoma screening. Dig Dis Sci. 2012;57:2910–6.PubMedView ArticleGoogle Scholar
- Benson 3rd AB, Abrams TA, Ben-Josef E, Bloomston PM, Botha JF, Clary BM, et al. NCCN clinical practice guidelines in oncology: hepatobiliary cancers. J Natl Compr Canc Netw. 2009;7:350–91.PubMed CentralPubMedGoogle Scholar
- Qu KZ, Zhang K, Li H, Afdhal NH, Albitar M. Circulating microRNAs as biomarkers for hepatocellular carcinoma. J Clin Gastroenterol. 2011;45:355–60.PubMedView ArticleGoogle Scholar
- Chen Q, Chen X, Zhang M, Fan Q, Luo S, Cao X. miR-137 is frequently down-regulated in gastric cancer and is a negative regulator of Cdc42. Dig Dis Sci. 2011;56:2009–16.PubMedView ArticleGoogle Scholar
- Visone R, Petrocca F, Croce CM. Micro-RNAs in gastrointestinal and liver disease. Gastroenterology. 2008;135:1866–9.PubMedView ArticleGoogle Scholar
- Garzon R, Heaphy CE, Havelange V, Fabbri M, Volinia S, Tsao T, et al. MicroRNA 29b functions in acute myeloid leukemia. Blood. 2009;114:5331–41.PubMed CentralPubMedView ArticleGoogle Scholar
- Chen X, Ba Y, Ma L, Cai X, Yin Y, Wang K, et al. Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res. 2008;18:997–1006.PubMedView ArticleGoogle Scholar
- Gilad S, Meiri E, Yogev Y, Benjamin S, Lebanony D, Yerushalmi N, et al. Serum microRNAs are promising novel biomarkers. PLoS One. 2008;3:e3148.PubMed CentralPubMedView ArticleGoogle Scholar
- Zheng D, Haddadin S, Wang Y, Gu LQ, Perry MC, Freter CE, et al. Plasma microRNAs as novel biomarkers for early detection of lung cancer. Int J Clin Exp Pathol. 2011;4:575–86.PubMed CentralPubMedGoogle Scholar
- Huang Z, Huang D, Ni S, Peng Z, Sheng W, Du X. Plasma microRNAs are promising novel biomarkers for early detection of colorectal cancer. Int J Cancer. 2010;127:118–26.PubMedView ArticleGoogle Scholar
- Di Masi A, Viganotti M, Antoccia A, Magrelli A, Salvatore M, Azzalin G, et al. Characterization of HuH6, Hep3B, HepG2 and HLE liver cancer cell lines by WNT/beta - catenin pathway, microRNA expression and protein expression profile. Cell Mol Biol (Noisy-le-Grand). 2010;56(Suppl):OL1299–317.Google Scholar
- Varnholt H. The role of microRNAs in primary liver cancer. Ann Hepatol. 2008;7:104–13.PubMedGoogle Scholar
- Dienstag JL. Hepatitis B virus infection. N Engl J Med. 2008;359:1486–500.PubMedView ArticleGoogle Scholar
- Johnson PJ, Melia WM, Palmer MK, Portmann B, Williams R. Relationship between serum alpha-foetoprotein, cirrhosis and survival in hepatocellular carcinoma. Br J Cancer. 1981;44:502–5.PubMed CentralPubMedView ArticleGoogle Scholar
- Farinati F, Rinaldi M, Gianni S, Naccarato R. How should patients with hepatocellular carcinoma be staged? Validation of a new prognostic system. Cancer. 2000;89:2266–73.PubMedView ArticleGoogle Scholar
- Koberle V, Kronenberger B, Pleli T, Trojan J, Imelmann E, Peveling-Oberhag J, et al. Serum microRNA-1 and microRNA-122 are prognostic markers in patients with hepatocellular carcinoma. Eur J Cancer. 2013;49:3442–9.PubMedView ArticleGoogle Scholar
- European Association For The Study Of The Liver; European Organisation For Research And Treatment Of Cancer. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2012;56:908–43.View ArticleGoogle Scholar
- Kojiro M, Roskams T. Early hepatocellular carcinoma and dysplastic nodules. Semin Liver Dis. 2005;25:133–42.PubMedView ArticleGoogle Scholar
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.